Theriva Biologics, Inc. (TOVX)
| Market Cap | 14.41M +700.6% |
| Revenue (ttm) | 300,000 |
| Net Income | -22.97M |
| EPS | -1.06 |
| Shares Out | 45.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,298,933 |
| Open | 0.2912 |
| Previous Close | 0.2966 |
| Day's Range | 0.2912 - 0.3149 |
| 52-Week Range | 0.1628 - 0.8632 |
| Beta | 1.17 |
| Analysts | Buy |
| Price Target | 2.50 (+696.18%) |
| Earnings Date | May 5, 2026 |
About TOVX
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral c... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for TOVX stock is "Buy." The 12-month stock price target is $2.5, which is an increase of 696.18% from the latest price.
News
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –
Theriva Biologics Earnings release: Q1 2026
Theriva Biologics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Theriva Biologics Quarterly report: Q1 2026
Theriva Biologics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Theriva Biologics Proxy statement: Proxy filing
Theriva Biologics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Theriva Biologics Proxy statement: Proxy filing
Theriva Biologics filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Theriva Biologics to present additional data on Phase 2b VCN-01Clinical Trial
Theriva Biologics (TOVX) “announced an upcoming poster presentation of new data and subgroup analyses from the VIRAGE Phase 2b clinical trial evaluating VCN-01 (zabilugene almadenorepvec) plus gemcita...
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients a...
Theriva Biologics upgraded to Buy at Maxim on clearer VCN-01 path
As previously reported, Maxim Jason McCarthy upgraded Theriva Biologics (TOVX) to Buy from Hold with a $1 price target The firm says the the path forward for VCN-01 in first-line…
Theriva Biologics upgraded to Buy from Hold at Maxim
Maxim upgraded Theriva Biologics (TOVX) to Buy from Hold with a $1 price target
Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA
Theriva Biologics (TOVX) announced the outcomes of a recent Type B End-of-Phase 2 meeting with the FDA regarding the design of a Phase 3 clinical study of lead clinical candidate…
Theriva Biologics Proxy statement: Proxy Filing
Theriva Biologics filed a proxy statement on March 16, 2026, providing details for shareholder voting and corporate governance matters.
Theriva Biologics price target lowered to $4 from $7 at Alliance Global
Alliance Global lowered the firm’s price target on Theriva Biologics (TOVX) to $4 from $7 and keeps a Buy rating on the shares following the Q4 report. The firm cites…
Theriva Biologics reports FY25 EPS ($2.08) vs. ($19.03) last year
“We are very pleased to have completed the licensing of our versatile Phase 2-ready asset SYN-020 to Rasayana Therapeutics, executing on our plan to derive value from our GI portfolio…
Theriva Biologics sees cash runway into 1Q27
Cash and cash equivalents totaled $13.1 million as of December 31, 2025, compared to $11.6 million as of December 31, 2024. The Company’s current cash of approximately $15.2 million at…
Theriva Biologics Earnings release: Q4 2025
Theriva Biologics released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Theriva Biologics Annual report: Q4 2025
Theriva Biologics has published its Q4 2025 annual report on March 12, 2026.
Theriva Biologics Proxy statement: Proxy Filing
Theriva Biologics filed a proxy statement on March 4, 2026, providing details for shareholder voting and corporate governance matters.
Theriva Biologics licenses SYN-020 to Rasayana Therapeutics
Theriva Biologics (TOVX) reported the out-licensing of SYN-020, to Rasayana Therapeutics, a privately-held company targeting the Gut-Organ axis biology to discover and deliver transformative gut-targe...
Theriva Biologics Proxy statement: Proxy Filing
Theriva Biologics filed a proxy statement on January 5, 2026, providing details for shareholder voting and corporate governance matters.
Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design
Theriva Biologics (TOVX) announced the receipt of Scientific Advice from the Committee for Medicinal Products for Human Use of the European Medicines Agency on the design of a Phase 3…
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC , including sample si...
Theriva Biologics Proxy statement: Proxy Filing
Theriva Biologics filed a proxy statement on December 23, 2025, providing details for shareholder voting and corporate governance matters.
Theriva Biologics reports Q3 EPS (45c) vs ($6.81) last year
“Recent presentations of clinical data for VCN-01 and preclinical data for VCN-12 at medical congresses have highlighted the progress made across our oncology pipeline,” said Steven A. Shallcross, Chi...
Theriva Biologics Quarterly report: Q3 2025
Theriva Biologics has published its Q3 2025 quarterly earnings report on November 12, 2025.
Theriva Biologics Earnings release: Q3 2025
Theriva Biologics released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.